Related Experiment Video
Updated: Jan 28, 2026

Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
Current concepts in oligometastatic prostate cancer: Is there a role for radical prostatectomy?
Jose Marenco1, Prasanna Sooriakumaran2
1University College London Hospital. NHS Foundation Trust. London. UK.
Introduction:
Prostate cancer is the most common solid organ malignancy in men. Despite the implementation of PSA screening, the incidence of metastatic prostate cancer in Spain is still around 4%. In this clinical scenario, systemic treatment is the gold standard. Cytoreductive surgery is a standard approach for some solid organ metastatic tumours. Recently there isinterest in exploring the clinical benefit of local treatment (LT) to the primary site in oligometastatic prostate cancer.
Materials And Methods:
Review of the relevant literature to evaluate the benefit of local treatment (LT) in metastatic prostate cancer.
Results:
Local treatment of the primary tumour has demonstrated oncological and symptomatic benefit in other malignancies. Multimodal therapies have demonstrated oncological and symptomatic benefit in locally advanced prostate cancer. Furthermore, surgery has been shown to reduce symptomatic progression in metastatic prostate cancer.
Conclusion:
The role of surgery to the primary site or metastasis directed treatment is currently being investigated, in the context of oligometastatic prostate cancer. Retrospective data provide a rationale for ongoing randomized controlled trials in this area. New imaging modalities might have a great impact in this conceptual change. Further data is still needed to recommend this approach as a standard of care.
Insights
Local treatment may benefit select prostate cancer patients with limited metastases. Research is ongoing to determine if primary site treatment improves outcomes in oligometastatic prostate cancer, potentially changing standard care.
Area of Science:
- Urology
- Oncology
- Surgical Oncology
Background:
- Prostate cancer is a leading malignancy in men, with metastatic disease occurring in approximately 4% of cases despite PSA screening.
- Systemic therapy is the current standard for metastatic prostate cancer, while cytoreductive surgery is established for other metastatic solid tumors.
Purpose of the Study:
- To review the literature evaluating the potential benefits of local treatment (LT) to the primary tumor in patients with metastatic prostate cancer.
- To assess the role of LT in the context of oligometastatic prostate cancer.
Main Methods:
- A comprehensive review of existing literature was conducted.
- The focus was on studies investigating local treatment for primary prostate cancer in the setting of metastatic disease.
Main Results:
- Local treatment of primary tumors has shown oncological and symptomatic benefits in other cancers.
- Surgery has demonstrated a reduction in symptomatic progression for metastatic prostate cancer patients.
Conclusions:
- The role of primary site surgery or metastasis-directed treatment is under investigation for oligometastatic prostate cancer.
- Retrospective data support ongoing randomized trials, with new imaging potentially influencing this paradigm shift.
- More data are required before local treatment can be recommended as standard of care for metastatic prostate cancer.
Related Concept Videos
Self-Concept
Infancy and Emerging Recognition
During infancy, self-concept is virtually nonexistent. Babies do not distinguish themselves as separate entities and often mistake their...
Radical Reactivity: Nucleophilic Radicals
Radical Reactivity: Electrophilic Radicals
Formula Mass and Mole Concepts of Compounds
Concepts and Prototypes
The brain organizes this information using concepts, which are mental categories grouping linguistic data,...
Radical Autoxidation

